GSK: Back in the Dock
Deny, disavow and disagree.
Last week, we told you about GSK's woes, how crime paid, and how they celebrated their latest win in the Zantac litigation.
Despite celebrating a legal victory in the Zantac litigation, GSK's triumph was short-lived. A Delaware judge allowed 70,000 lawsuits against GSK to proceed to trial.
The decision, based on expert testimony linking the drug to cance…